OCA
AMLX icon

Octagon Capital Advisors’s Amylyx Pharmaceuticals AMLX Stock Holding History

Octagon Capital Advisors’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-695,000
Closed -$12.7M – 34
2023
Q3 		$12.7M Buy
+695,000
New +$14.7M 1.96% 17

Other funds holding AMLX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Octagon Capital Advisors's AMLX Position: Q4 2023 in Review

Octagon Capital Advisors sold out of Amylyx Pharmaceuticals (AMLX) in Q4 2023, closing a stake of 695,000 shares — an estimated $12.7M sold.

Octagon Capital Advisors first reported a position in AMLX in Q3 2023 and held it in 1 quarter. The position peaked at $12.7M in Q3 2023. 178 funds tracked by Wall St. Rank hold AMLX as of Q4 2023.

  • Octagon Capital Advisors reported no remaining Amylyx Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 695,000 Amylyx Pharmaceuticals shares in Q4 2023, an estimated $12.7M.
  • Octagon Capital Advisors first reported a position in Amylyx Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Octagon Capital Advisors's Amylyx Pharmaceuticals position peaked at $12.7M in Q3 2023.
  • 178 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.